138 related articles for article (PubMed ID: 25520130)
1. Serum periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder.
Matsumoto K; Ikeda M; Matsumoto T; Nagashio R; Nishimori T; Tomonaga T; Nomura F; Sato Y; Kitasato H; Iwamura M
Asian Pac J Cancer Prev; 2014; 15(22):9927-31. PubMed ID: 25520130
[TBL] [Abstract][Full Text] [Related]
2. High expression level of preoperative serum Uroplakin III is associated with biologically aggressive bladder cancer.
Tsumura H; Matsumoto K; Ikeda M; Yanagita K; Hirano S; Hagiwara M; Nagashio R; Fujita T; Sato Y; Iwamura M
Asian Pac J Cancer Prev; 2015; 16(4):1539-43. PubMed ID: 25743828
[TBL] [Abstract][Full Text] [Related]
3. Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma of the urinary bladder.
Srivastava AK; Singh PK; Rath SK; Dalela D; Goel MM; Bhatt ML
Tumour Biol; 2014 Nov; 35(11):11435-42. PubMed ID: 25123267
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer.
Shabayek MI; Sayed OM; Attaia HA; Awida HA; Abozeed H
Pathol Oncol Res; 2014 Oct; 20(4):859-66. PubMed ID: 24696417
[TBL] [Abstract][Full Text] [Related]
5. Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder.
Matsumoto K; Ikeda M; Sato Y; Kuruma H; Kamata Y; Nishimori T; Tomonaga T; Nomura F; Egawa S; Iwamura M
Biomed Res; 2014; 35(3):201-6. PubMed ID: 24942859
[TBL] [Abstract][Full Text] [Related]
6. Expression of miR-100 as a novel ancillary non-invasive biomarker for early detection of bladder carcinoma.
Qureshi A; Fahim A; Kazi N; Farsi Kazi SA; Nadeem F
J Pak Med Assoc; 2018 May; 68(5):759-763. PubMed ID: 29885177
[TBL] [Abstract][Full Text] [Related]
7. uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses.
Comploj E; Mian C; Ambrosini-Spaltro A; Dechet C; Palermo S; Trenti E; Lodde M; Horninger W; Pycha A
Cancer Cytopathol; 2013 Jul; 121(7):392-7. PubMed ID: 23495066
[TBL] [Abstract][Full Text] [Related]
8. Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma.
Li JR; Chiu KY; Ou YC; Wang SS; Chen CS; Yang CK; Ho HC; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Hung SC; Hsu CY; Chen CJ
Biofactors; 2019 Jan; 45(1):62-68. PubMed ID: 30334297
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
[TBL] [Abstract][Full Text] [Related]
10. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
11. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma.
Svatek RS; Karam J; Karakiewicz PI; Gallina A; Casella R; Roehrborn CG; Shariat SF
J Urol; 2008 Feb; 179(2):478-84; discussion 484. PubMed ID: 18076936
[TBL] [Abstract][Full Text] [Related]
12. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
[TBL] [Abstract][Full Text] [Related]
13. Urinary cytology for the detection of urothelial carcinoma of the bladder--a flawed adjunct to cystoscopy?
Bolenz C; West AM; Ortiz N; Kabbani W; Lotan Y
Urol Oncol; 2013 Apr; 31(3):366-71. PubMed ID: 21414815
[TBL] [Abstract][Full Text] [Related]
14. Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.
Fang Z; Dai W; Wang X; Chen W; Shen C; Ye G; Li L
Tumour Biol; 2016 Jun; 37(6):8075-82. PubMed ID: 26715266
[TBL] [Abstract][Full Text] [Related]
15. SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer.
Keck B; Wach S; Goebell PJ; Kunath F; Bertz S; Lehmann J; Stöckle M; Taubert H; Wullich B; Hartmann A
Ann Surg Oncol; 2013 Oct; 20(11):3669-74. PubMed ID: 23807662
[TBL] [Abstract][Full Text] [Related]
16. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
17. Independent prognostic value of serum hepatocyte growth factor in bladder cancer.
Gohji K; Nomi M; Niitani Y; Kitazawa S; Fujii A; Katsuoka Y; Nakajima M
J Clin Oncol; 2000 Aug; 18(16):2963-71. PubMed ID: 10944129
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of TRPM8 is associated with poor prognosis in urothelial carcinoma of bladder.
Xiao N; Jiang LM; Ge B; Zhang TY; Zhao XK; Zhou X
Tumour Biol; 2014 Nov; 35(11):11499-504. PubMed ID: 25128062
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of semaphorin 3A in patients with urothelial cancer.
Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
[TBL] [Abstract][Full Text] [Related]
20. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment.
Avgeris M; Mavridis K; Tokas T; Stravodimos K; Fragoulis EG; Scorilas A
Carcinogenesis; 2015 May; 36(5):528-37. PubMed ID: 25804644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
